Search Results

Adaptilens, Inc., a pre-clinical company dedicated to transforming the standard of care for cataract surgery, announced the closing of a Series A financing round of $17.5 million led by Perceptive Xontogeny Venture Funds, with additional investments from Pillar VC, 380 Cap, and Accanto Partners.

Neurosterix, a biopharmaceutical company dedicated to the development of allosteric modulator therapeutics for underserved neurological disorders, launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures.

Xontogeny LLC, a Boston-based accelerator that provides seed-stage investments along with strategic and operational support to early-stage life science companies, unveiled five of its latest portfolio companies.

Delve Bio debuts with $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II (PXV Fund II) – and joined by Section 32 and GV.

Juno Diagnostics, a company focused on improving access to vital genetic health information and led by industry experts, announced the closing of an expanded Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund.

Tellus Therapeutics announced today the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund.

Peroxitech Inc. announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (“PXV Fund”).

Perceptive Advisors, an investment management firm focused in life sciences, today announced the closing of its inaugural venture capital fund, the Perceptive Xontogeny Venture Fund, LP (the “PXV Fund”), solely focused on investment in early-stage life science companies.

PolyCore Therapeutics, Inc., a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, today announced a seed investment from Xontogeny, LLC and Ben Franklin Technology Partners of Southeastern Pennsylvania to advance their lead compound, PCT-3012.